Galapagos NV (NASDAQ:GLPG) Receives Consensus Rating of “Reduce” from Analysts

Galapagos NV (NASDAQ:GLPG) has received a consensus recommendation of “Reduce” from the nine brokerages that are presently covering the firm, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $31.3333.

GLPG has been the topic of several recent research reports. Leerink Partnrs upgraded Galapagos from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 22nd. Royal Bank Of Canada raised their price objective on Galapagos from $28.00 to $32.00 and gave the company a “sector perform” rating in a research note on Friday, November 7th. Weiss Ratings restated a “sell (d)” rating on shares of Galapagos in a report on Wednesday, October 8th. Leerink Partners set a $40.00 price target on Galapagos and gave the company an “outperform” rating in a report on Tuesday, October 21st. Finally, Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Galapagos in a research report on Tuesday, August 5th.

Institutional Investors Weigh In On Galapagos

A number of hedge funds have recently bought and sold shares of GLPG. Monaco Asset Management SAM grew its position in shares of Galapagos by 140.2% in the first quarter. Monaco Asset Management SAM now owns 36,036 shares of the biotechnology company’s stock valued at $905,000 after purchasing an additional 21,036 shares during the last quarter. Wealthquest Corp bought a new stake in Galapagos during the 1st quarter valued at approximately $74,000. ABC Arbitrage SA bought a new position in Galapagos in the 1st quarter worth approximately $333,000. Tejara Capital Ltd bought a new position in Galapagos in the 1st quarter worth approximately $1,351,000. Finally, American Century Companies Inc. lifted its holdings in shares of Galapagos by 7.7% during the first quarter. American Century Companies Inc. now owns 27,839 shares of the biotechnology company’s stock worth $699,000 after buying an additional 1,987 shares during the last quarter. 32.46% of the stock is currently owned by institutional investors.

Galapagos Stock Down 2.5%

Shares of GLPG opened at $31.49 on Friday. The firm has a market cap of $2.08 billion, a price-to-earnings ratio of -20.06 and a beta of 0.23. The company’s fifty day moving average is $32.98 and its 200-day moving average is $30.82. Galapagos has a 12 month low of $22.36 and a 12 month high of $37.78.

Galapagos Company Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.